HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Regorafenib-13C-d3

HCID 178542460
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
2126178-55-8
Standard SMILES
[2H][13C]([2H])([2H])NC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
InChIKey
FNHKPVJBJVTLMP-KQORAOOSSA-N
Molecular formula
C21H15ClF4N4O3
Average molar mass
486.8 g/mol
Monoisotopic mass
486.0990658

Names & identifiers

Preferred name
Regorafenib-13C-d3
IUPAC
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide
English name
Regorafenib-13C-d3
Molecular formula
C21H12ClD3F4N4O3
Molecular weight
486.842898134

Names & synonyms

Regorafenib-13C-d32126178-55-8Regorafenib-13C,d34-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamideorb2299884TMIJ-0124755037-03-7 (Unlabeled)HY-10331S1CS-03780284-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-(methyl-13C-d3)picolinamide4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluoro-phenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide

Database identifiers

CAS
2126178-55-8
PubChem CID
76974621

Properties

Computed structural propertiesFilling in

XLogP
4.2
Topological polar surface area
92.4 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
8
Rotatable bonds
5
Heavy atoms
33
Formal charge
0
Complexity
686

Physicochemical properties

storage temp.
-20 °C · Store at -20°C
solubility
30 mg/ml; · DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 14 mg/ml
form
A solid

Chemistry & industry

Applications · 1 item

DescriptionRegorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.1 It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.1,2,3 In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.1 It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes